Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Carcinoma, Renal Cell 6Brenner Tumor 6Melanoma 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colonic Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Rituximab 40Cyclophosphamide 29Etoposide 15Doxorubicin 14Vincristine 13Prednisone 13ibrutinib 10fludarabine 10fludarabine phosphate 8Cytarabine 8Mycophenolic Acid 7Bortezomib 7Lenalidomide 6Carmustine 6pembrolizumab 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Inotuzumab Ozogamicin 5Whole-Body Irradiation 4Tacrolimus 4Carboplatin 4CT-P10 4Brentuximab Vedotin 4Antilymphocyte Serum 4tositumomab I-131 3tocilizumab 3tazemetostat 3obinutuzumab 3idelalisib 3etoposide phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell × Disulfides × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡